Fifty years of travel medicine epidemiology: what have we learnt? by Steffen, Robert & Wilson, Mary E








Fifty years of travel medicine epidemiology: what have we learnt?
Steffen, Robert; Wilson, Mary E
DOI: https://doi.org/10.1093/inthealth/ihv035





Steffen, Robert; Wilson, Mary E (2015). Fifty years of travel medicine epidemiology: what have we
learnt? International Health, 7(6):375-376.
DOI: https://doi.org/10.1093/inthealth/ihv035
Fifty years of travel medicine epidemiology: what have we learnt?
Robert Steffena,b,* and Mary E. Wilsonc,d
aDivision of Infectious Diseases, Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, WHO Collaborating
Center for Traveller’s Health, University of Zurich, Zurich, Switzerland; bDivision of Epidemiology, Human Genetics & Environmental
Sciences, The University of Texas School of Public Health, Houston, Texas, USA; cDepartment of Global Health and Population, Harvard T.H.
Chan School of Public Health, Boston, Massachusetts, USA; dGlobal Health Sciences, University of California San Francisco, California, USA
*Corresponding author: Tel: +41 79 292 7832; E-mail: roste@ifspm.uzh.ch
Received 25 February 2015; revised 26 April 2015; accepted 30 April 2015
Keywords: Epidemiology, Evidence, Prevention, Risk, Travel
In the late1950s, Pan Am ﬂight 2 from Calcutta to New York was
scheduled to take almost 50 hours. Only after the introduction of
jet airliners in the 1960s, did intercontinental travel becomemore
common. Increasingly, that included journeys to developing
countries, and tourist hotels and safari lodges were established
in Kenya and elsewhere. While anecdotal reports on imported
exotic infections were collated, except for military publications,
there was a lack of epidemiological assessment of health risks
associated with travel. Until chloroquine resistance emerged,
that agent was unanimously recommended for prophylaxis of
malaria. In contrast, widely differing ‘expert opinions’ on indicated
travel health vaccines, mainly against cholera, plague, typhoid/
paratyphoid and typhus, were formulated. As late as 1969,
health certiﬁcates guaranteeing that travelers were ‘not suffering
from trachoma, leprosy, dysentery, acute epilepsy and insanity’
were required by some authorities.
In the 1970s, researchers on both sides of the Atlantic realized
that data were needed to develop evidence-based priorities with
respect to preventive measures for travelers. According to a
postcard-questionnaire survey among passengers arriving at US
airports, almost one in four reported some illness, most often tra-
velers’ diarrhea, but the response rate was <30%.1 A Scottish re-
search group assessed health problems in package tourists,
mainly to eastern Europe. Our group in Switzerland systematically
investigated health problems abroad in homebound charter ﬂight
passengers; the response rate exceeded 80%.2We conﬁrmed that
travelers’ diarrheawas themost frequent illness in any developing
country. Rates widely differed depending on the destination. In
contrast, in the control group of visitors to North America, consti-
pation was the most frequent ailment. Later, from hospital and
public health records and traveler statistics we estimated the inci-
dence rate of hepatitis (at that time 1 per 300 permonth), typhoid
(greatest risk in South Asia) and other vaccine-preventable dis-
eases.3 The highest mortality (15 per 100 000) was recorded
during treks in Nepal.4 Injuries were the leading cause of death
among travelers in low-income countries, whereas cardiovascular
events dominated in the Caribbean and southern Europe where
many senior travelers spent the winter season. A completely
different approach to illustrate infectious risks abroad was to
describe the epidemiological situation in the individual countries
while recognizing that risks to visitors and local residents and
clinical manifestations of infections may differ between the
two groups.5 With lack of funding these early studies had a
simple design; most were retrospective and thus subject to
recall bias. Self-reporting of symptoms was suboptimal and
many studies did not include statistical analysis. In the few
cohort studies, conclusions were drawn on very small numbers.
In the absence of good data, case reports, clusters and anecdotes
drove decisions.
In 1995 the International Society of Travel Medicine jointly with
the U.S. Centers for Disease Control and Prevention established
GeoSentinel, a global surveillance network currently including 57
clinics on all continents. These are situated to effectively detect
geographic and temporal trends in morbidity among travelers,
immigrants and refugees. More than 50 publications describe re-
gional and seasonal trends, speciﬁc infections and syndromes,
and risks associated with various host factors, such as age or
reason for travel. Lacking of denominator data, the network is
unable to provide incidence rates, and can document only a rela-
tive risk as compared to other diagnoses. But GeoSentinel has
recognized sentinel events, prompting enhanced surveillance,
and has detected outbreaks (e.g., dengue) before the national au-
thorities had identiﬁed them. Thanks to rapid communication,
athletes potentially infected by leptospira during an Eco-
Challenge race in Sabah, could be alerted in time for intervention.6
Since the turn of the century, a myriad of anecdotal reports on
travel-related infections have been published, of particular interest
are those on very rare ones.7 Japanese encephalitis affects about
one in a million travelers to endemic countries,7 and it is an illusion
to believe that all cases could be collated in some global registry.
© The Author 2015. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.







Int Health 2015; 7: 375–376
doi:10.1093/inthealth/ihv035 Advance Access publication 14 June 2015
375
Recent observational and cohort studies have documented a de-
creasing risk of hepatitis A7,8 and travelers’ diarrhea,7,9 possibly
associatedwith improved sanitary conditions in some destinations.
Also, there is increasing interest on sequelae thereof, mainly irrit-
able bowel syndrome.10 Various groups provided detailed insight
in risks among special populations, such as the immunodeﬁcient
a population that is growing in size and is also traveling.
Changes in the epidemiology of some infections, increases in
antimicrobial drug resistance (e.g., typhoid fever), concerns sub-
sequent to the widespread importation of extended-spectrum
beta-lactamase producing Enterobacteriaceae,11 the availability
of new vaccines and malaria chemoprophylactic agents with dif-
ferent efﬁcacy and adverse event proﬁles require rethinking of
recommendations for travelers. Risk is not ﬁxed and potential
interventions change; thus, ongoing assessment and analysis is
required. The relevant population to study to assess the risk to tra-
velers is all travelers.
The internet and electronic networks allow rapid wide sharing
of information but these do not replace the need for systematic
collection of data. Although many publications are based on
data from travel clinics, these clinics see a minority of travelers,
and these travelers may differ substantially from all travelers. In-
creasingly, the traveling public includes older individuals and
those with chronic medical problems. Also, migrants who later
visit friends and relatives (VFR) are of particular concern. This
group has limited ﬁnancial means for pre-travel consultations
and prophylactic products. VFR often do not perceive infection
risks ‘back home’, whichmay be a threat particularly for their over-
seas born children, and for a variety of reasons, e.g., relating to
language, there are problems of access to travel health providers.
Despite a rapidly increasing number of publications, travel epi-
demiology is far fromwhere it should be. Since 2012,WHOhas not
published the annual International Travel and Health, as many
recommendations are based on data that are graded to be of
substandard quality.7,12 For the development of modern guide-
lines we need a risk assessment based on 21st century
state-of-the-art trials.7 Also of concern is the misinterpretation
of published results. For example, it is inappropriate to draw con-
clusions that mainly women should be equipped with stand by
antidiarrheal medication, subsequent to the ﬁnding that they
consulted with GeoSentinel travel clinics that stated that diarrhea
occurs more often than in men (OR 1.13; 95% CI 1.09–1.38),
when most large previous studies had shown no gender-related
differences in incidence. Actually the authors had carefully formu-
lated, ‘it is unclear whether women practice travel behavior that
increases the risk of acquiring gastrointestinal pathogens or
whether they are more likely than men to seek medical help for
gastrointestinal problems’.13
Many important questions remain unresolved: is the biological-
ly plausible rule, ‘boil it, cook it, peel it, or forget it’, really useless to
avoid diarrhea abroad14 and, if so, why? Why does travel health
advice ‘not protect… from travel-related illness,’15 are our efforts
useless? Travel clinics can provide vaccines and drugs, but how
does one change behavior? Novel studies, multicenter collabora-
tions to generate large denominators are needed to bring us a
step further. Large travel clinics now have the electronic capability
to conduct a follow-up on customers, but as this is a biased popu-
lation we should also ﬁnd means to recruit departing passengers
e.g., at airports. Other questions remain. Can we engage travelers
to provide ‘during’ aswell as ‘after-travel’ data thatwill allow iden-
tiﬁcation of before and during travel interventions that are effect-
ive? Can we harness today’s tools to generate data to
complement ﬁndings from trials?
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